AI Article Synopsis
Article Abstract
Purpose: In this phase I study, we evaluated the safety, biodistribution and dosimetry of [Zr]Zr-DFO-girentuximab (Zr-girentuximab) PET/CT imaging in patients with suspicion of clear cell renal cell carcinoma (ccRCC).
Methods: Ten eligible patients received an intravenous administration of 37 MBq (± 10%) of Zr-girentuximab at mass doses of 5 mg or 10 mg. Safety was evaluated according to the NCI CTCAE (version 4.03). Biodistribution and normal organ dosimetry was performed based on PET/CT images acquired at 0.5, 4, 24, 72 and 168 h post-administration. Additionally, tumour dosimetry was performed in patients with confirmed ccRCC and visible tumour uptake on PET/CT imaging.
Results: Zr-girentuximab was administered in ten patients as per protocol. No treatment-related adverse events ≥ grade 3 were reported. Zr-girentuximab imaging allowed successful differentiation between ccRCC and non-ccRCC lesions in all patients, as confirmed with histological data. Dosimetry analysis using OLINDA/EXM 2.1 showed that the organs receiving the highest doses (mean ± SD) were the liver (1.86 ± 0.40 mGy/MBq), the kidneys (1.50 ± 0.22 mGy/MBq) and the heart wall (1.45 ± 0.19 mGy/MBq), with a mean whole body effective dose of 0.57 ± 0.08 mSv/MBq. Tumour dosimetry was performed in the 6 patients with histologically confirmed ccRCC resulting in a median tumour-absorbed dose of 4.03 mGy/MBq (range 1.90-11.6 mGy/MBq).
Conclusions: This study demonstrates that Zr-girentuximab is safe and well tolerated for the administered activities and mass doses and allows quantitative assessment of Zr-girentuximab PET/CT imaging in patients with suspicion of ccRCC.
Trial Registration: NCT03556046-14th of June, 2018.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8426244 | PMC |
| http://dx.doi.org/10.1007/s00259-021-05271-w | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Validation of a diode-based phantom for high temporal and spatial measurements in a 1.5 T MR-linac.
J Appl Clin Med Phys
December 2024
Department of Radiotherapy, University Medical Center Utrecht, Utrecht, Netherlands.
Background: For the development and validation of dynamic treatment modalities and processes on the MR-linac, independent measurements should be performed that validate dose delivery and linac behavior at a high temporal resolution. To achieve this, a detector with both high temporal and spatial resolution is necessary.
Purpose: This study investigates the suitability of a Delta4 Phantom+ MR (Delta4) detector array for time-resolved dosimetry in the 1.
Impact of MRI-based planning in transperineal interstitial brachytherapy for vaginal-involving tumors.
J Contemp Brachytherapy
October 2024
Radiotherapy Department, Hospital Clínica Benidorm, Benidorm, Alicante, Spain.
Purpose: The purpose of the study was to analyze patients with vaginal-involving recurrences of gynecological tumors and primary vaginal tumors, treated with transperineal interstitial brachytherapy (P-ISBT). Dosimetric, clinical, and toxicity analysis of these patients was conducted, incorporating MRI in volume definition and dose-volume dosimetry.
Material And Methods: Forty-two patients were retrospectively analyzed.
Sensitivity of contributing factors to heterogeneity corrections in dosimetry of ocular brachytherapy using iodine-125 COMS plaques.
J Contemp Brachytherapy
October 2024
Department of Radiation Oncology, East Carolina University, Greenville, North Carolina, USA.
Purpose: To investigate sensitivity of contributing factors to heterogeneity corrections in ocular brachytherapy using iodine-125 (I) Collaborative Ocular Melanoma Study (COMS) plaques.
Material And Methods: Using egs_brachy, Monte Carlo (MC) simulations were performed for I COMS plaques (model: IsoAid IAI-125A). Homogeneous dose (D) was estimated under the American Association of Physicists in Medicine Task Group-43 assumptions, with 85 Gy prescribed to a 5 mm depth.
Where are we with fractionation schedules and prescriptions in high-dose-rate 3D planning vaginal cuff brachytherapy?
J Contemp Brachytherapy
October 2024
Fonaments Clinics Department, Universitat de Barcelona, Barcelona, Spain.
Purpose: Currently, there are many schedules for exclusive vaginal cuff brachytherapy (VCB). In 3D treatment planning for VCB dosimetry, parameters have not been analyzed. The aim of this study was to compare the most common schedules using dose-volume histogram metrics.
View Article and Find Full Text PDFDermal penetration of 2-phenoxyethanol in humans: in vivo metabolism and toxicokinetics.
Arch Toxicol
December 2024
Institute and Outpatient Clinic of Occupational, Social and Environmental Medicine, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
2-Phenoxyethanol (PhE) is an amphiphilic organic compound frequently used as a broad-spectrum preservative in cosmetic products and other consumer goods. PhE is also used as a biocidal component in occupational settings. A previous volunteer study by our working group following oral exposure to PhE showed that PhE is almost completely taken up into the human body followed by an extensive metabolization and fast urinary elimination.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!